Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
Perindopril + amlodipine + if necessary, hydrochlorothiazide
olmesartan/amlodipine + hydrochlorothiazide, if necessary.
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Sevikar®, Central Arterial Blood Pressure
Eligibility Criteria
Inclusion Criteria:
- moderate to severe hypertension
- 3 additional risk factors such as age > 55 (male), > 65 female, smoker, type 2 diabetes, obesity, cardiovascular disease, congestive heart failure, chronic kidney disease,
- ability to give informed consent
Exclusion Criteria:
- secondary or malignant hypertension
- contraindication to any of the study drugs
- Creatinine clearance level <40ml/min
- treatment with more than 3 antihypertensive drugs
- Myocardial infarction, percutaneous transluminal coronary angioplasty, cardiac bypass surgery < 6 month prior to start of the study,
- unstable angina pectoris,
- stroke, transient ischemic attack < 3 months prior to start,
- Congestive heart failure NYHA II-IV,
- clinically relevant concomitant diseases,
- alcohol or drug abuse,
- pregnancy or women of childbearing potential without contraceptive precaution,
Sites / Locations
- Centro de Salud Casas Ibañez
- Hospital del Mar
- Hospital General de Jerez de la Frontera
- Hospital Universitario de Fuenlabrada
- Hospital Universitario La Princesa
- Hospital Universitario 12 Octubre
- Hospital General Universitario La Paz
- Hospital Universitario Clínico San Carlos
- Hospital Universitario de Móstoles
- Hospital Universitario Ramón y Cajal
- Hospital General Carlos Haya
- Centro de Salud Murcia San Andrés
- Hospital de Sagunto
- Centro de Salud La Alamedilla
- Hospital Virgen de la Macarena
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Perindopril+amlodipine
Olmesartan/amlodipine
Arm Description
Outcomes
Primary Outcome Measures
Change in central systolic blood pressure from baseline (Week 0, Visit 0) to Final Examination (Week 24, Visit 5) using last observation carried forward approach.
Secondary Outcome Measures
Changes in systolic and diastolic ambulatory blood pressure (mean of 24h, daytime and night-time)
Changes in conventional mean sitting systolic and diastolic blood pressure measurement
Incidence and profile of AEs separately by Run-in Phase and by double-blind Treatment Phase
Number of responders at Final Examination defined as normalized or a decrease of systolic blood pressure by at least 20 mmHg or diastolic blood pressure by at least 10 mmHg in conventional BP measurements.
Number of normalized at Final Examination (defined as blood pressure <140/90 mmHg or <130/80 mmHg in diabetics/chronic kidney disease, in conventional BP measurements.
Changes in mean sitting systolic and diastolic blood pressure (BP) measurements from week 12 to Final Exam in patients with stabilized BP (BP is < 140/90 mmHg or < 130/80 mmHg for diabetics/chronic kidney disease) from Week 12 and Week 18.
Changes in Central Systolic Blood Pressure from week 12 to Final Examination in patients with stabilised BP (i.e. patients whose BP is < 140/90 mmHg or < 130/80 mmHg for diabetics/chronic kidney disease) between Week 12 and Week 18.
Full Information
NCT ID
NCT01101009
First Posted
April 7, 2010
Last Updated
December 20, 2018
Sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
1. Study Identification
Unique Protocol Identification Number
NCT01101009
Brief Title
Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure
Official Title
Efficacy of Sevikar® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension-
Study Type
Interventional
2. Study Status
Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Comparison of the combination of amlodipine with an angiotensin receptor blocker or an angiotensin converting inhibitor, on central arterial blood pressure in patients with hypertension and additional risk factors. This is a randomised, double-blind, double-dummy, multicenter study. The duration of active treatment 24 weeks.
Detailed Description
The study, multi-center balanced, parallel group (two treatment arms), randomized, double-blind (double-dummy), non-inferiority study is designed to show non-inferiority of Sevikar® (olmesartan(OM)/amlodipine (AM)) 40/10 mg compared to the combination of Perindopril (PER) 8 mg plus Amlodipine 10 mg with regard to central systolic blood pressure lowering effect, using the change from baseline (Week 0) to final examination (Week 24).
Male and female Caucasians aged ≥ 40 years and <80 years with moderate to severe hypertension, defined by a systolic blood pressure (SBP) ≥ 160 and ≤ 200 or diastolic blood pressure (DBP) ≥ 100 and ≤ 115 mmHg for untreated patients, SBP ≥ 140 or DBP ≥ 90 mmHg for insufficiently pre-treated patients and SBP ≥ 130 mmHg or DBP ≥ 80 mmHg for insufficiently pretreated diabetics chronic kidney disease will be eligible for participation. In addition,three additional risk factors should be present.
During the course of the study three central blood pressure measurements (at randomization, at week 12 and at termination) will be performed with SphygmoCor ultrasound method. The conventional measurements with calibrated tensiometers (Omron) will be performed at each visit. Ambulatory blood pressure monitoring will be performed at randomisation.
The study starts with a 2-4 week run in phase. AM will be given as open-labelled 5 mg or 10 mg tablets, administered once daily. After randomization during the double-blind phase, study medication will comprise either OM/AM 40/10 mg or PER 8 mg (2x4 mg) plus AM 10 mg and will be administered once daily. Furthermore, open-label HCTZ 12.5 mg and 25.0 mg will be provided in tablets and administered once daily according to the treatment schedule.
The primary endpoint is the change in central SBP from baseline (Week 0, Visit 0) to final examination (Week 24, Visit 5) using Last Observation Carried Forward (LOCF) approach.
The study is conducted in approximately 15 centres in Spain. Depending on the previously administered drugs the run in phase is up to four weeks (Visits -2 and -1). Individual duration of active treatment (after randomization) will last 24 weeks (Visits 0-5). The total individual duration is 28 weeks.
A total of 518 patients (259 patients/arm) will be needed in the Per Protocol Set (PPS) for the confirmatory primary analysis using mean change from baseline (Week 0) to Final Examination assuming a drop out rate of 20% during Run-in Phase a total of 720 patients have to be screened in order to achieve 576 (288 patients/arm) randomised patients.
Assuming approximately 10% major protocol deviations, a total of 518 patients will remain in the PPS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Sevikar®, Central Arterial Blood Pressure
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
486 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Perindopril+amlodipine
Arm Type
Active Comparator
Arm Title
Olmesartan/amlodipine
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Perindopril + amlodipine + if necessary, hydrochlorothiazide
Intervention Description
Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
Intervention Type
Drug
Intervention Name(s)
olmesartan/amlodipine + hydrochlorothiazide, if necessary.
Intervention Description
olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
Primary Outcome Measure Information:
Title
Change in central systolic blood pressure from baseline (Week 0, Visit 0) to Final Examination (Week 24, Visit 5) using last observation carried forward approach.
Time Frame
Baseline to week 24
Secondary Outcome Measure Information:
Title
Changes in systolic and diastolic ambulatory blood pressure (mean of 24h, daytime and night-time)
Time Frame
Baseline to week 24
Title
Changes in conventional mean sitting systolic and diastolic blood pressure measurement
Time Frame
Baseline to 24 weeks
Title
Incidence and profile of AEs separately by Run-in Phase and by double-blind Treatment Phase
Time Frame
Run in phase (2 weeks) to end of study (24 weeks)
Title
Number of responders at Final Examination defined as normalized or a decrease of systolic blood pressure by at least 20 mmHg or diastolic blood pressure by at least 10 mmHg in conventional BP measurements.
Time Frame
Baseline to 24 weeks
Title
Number of normalized at Final Examination (defined as blood pressure <140/90 mmHg or <130/80 mmHg in diabetics/chronic kidney disease, in conventional BP measurements.
Time Frame
Baseline to 24 weeks
Title
Changes in mean sitting systolic and diastolic blood pressure (BP) measurements from week 12 to Final Exam in patients with stabilized BP (BP is < 140/90 mmHg or < 130/80 mmHg for diabetics/chronic kidney disease) from Week 12 and Week 18.
Time Frame
Week 12 to Week 18 or week 24
Title
Changes in Central Systolic Blood Pressure from week 12 to Final Examination in patients with stabilised BP (i.e. patients whose BP is < 140/90 mmHg or < 130/80 mmHg for diabetics/chronic kidney disease) between Week 12 and Week 18.
Time Frame
Week 12 to week 18 or week 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
moderate to severe hypertension
3 additional risk factors such as age > 55 (male), > 65 female, smoker, type 2 diabetes, obesity, cardiovascular disease, congestive heart failure, chronic kidney disease,
ability to give informed consent
Exclusion Criteria:
secondary or malignant hypertension
contraindication to any of the study drugs
Creatinine clearance level <40ml/min
treatment with more than 3 antihypertensive drugs
Myocardial infarction, percutaneous transluminal coronary angioplasty, cardiac bypass surgery < 6 month prior to start of the study,
unstable angina pectoris,
stroke, transient ischemic attack < 3 months prior to start,
Congestive heart failure NYHA II-IV,
clinically relevant concomitant diseases,
alcohol or drug abuse,
pregnancy or women of childbearing potential without contraceptive precaution,
Facility Information:
Facility Name
Centro de Salud Casas Ibañez
City
Albacete
ZIP/Postal Code
02200
Country
Spain
Facility Name
Hospital del Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Hospital General de Jerez de la Frontera
City
Cadiz
ZIP/Postal Code
11407
Country
Spain
Facility Name
Hospital Universitario de Fuenlabrada
City
Fuenlabrada (Madrid)
Country
Spain
Facility Name
Hospital Universitario La Princesa
City
Madrid
ZIP/Postal Code
28006
Country
Spain
Facility Name
Hospital Universitario 12 Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Hospital General Universitario La Paz
City
Madrid
Country
Spain
Facility Name
Hospital Universitario Clínico San Carlos
City
Madrid
Country
Spain
Facility Name
Hospital Universitario de Móstoles
City
Madrid
Country
Spain
Facility Name
Hospital Universitario Ramón y Cajal
City
Madrid
Country
Spain
Facility Name
Hospital General Carlos Haya
City
Malaga
Country
Spain
Facility Name
Centro de Salud Murcia San Andrés
City
Murcia
Country
Spain
Facility Name
Hospital de Sagunto
City
Puerto De Sagunto (Valencia)
Country
Spain
Facility Name
Centro de Salud La Alamedilla
City
Salamanca
Country
Spain
Facility Name
Hospital Virgen de la Macarena
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing URL
https://vivli.org/ourmember/daiichi-sankyo/
Citations:
PubMed Identifier
24293132
Citation
Ruilope L, Schaefer A. The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension. Adv Ther. 2013 Dec;30(12):1086-99. doi: 10.1007/s12325-013-0076-6. Epub 2013 Nov 30. Erratum In: Adv Ther. 2014 Apr;31(4):472. Adv Ther. 2014 Feb;31(2):243. Adv Ther. 2015 Feb;32(2):184-5.
Results Reference
derived
PubMed Identifier
21586342
Citation
Ruilope LM, Schaefer A. Efficacy of Sevikar(R) compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study. Contemp Clin Trials. 2011 Sep;32(5):710-6. doi: 10.1016/j.cct.2011.04.011. Epub 2011 May 14.
Results Reference
derived
Learn more about this trial
Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure
We'll reach out to this number within 24 hrs